RAPP · Rapport Therapeutics, Inc.
AI read · Good for RAPP
The AI's read
That change signals greater optimism from one analyst. It does not report new trial results, sales, or a company forecast, so the positive read rests on the analyst's opinion.
Goldman Sachs raised its price goal for Rapport Therapeutics from $62 to $68.
Good for RAPP
Goldman Sachs kept its Buy rating on Rapport Therapeutics and raised its target from $62 to $68. This is favorable analyst opinion, not news of new trial results or company performance.
Get alerts for RAPP
Follow Rapport Therapeutics, Inc. (RAPP) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RAPPFree on the App Store and Google Play, or on the web.